Solutions for Tumor Heterogeneity
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides comprehensive solutions for the study of tumor heterogeneity, helping researchers successfully achieve their research goals.
Tumor heterogeneity is one of the characteristics of malignant tumors, which means that in the process of tumor growth, after multiple divisions and proliferations, its daughter cells show changes in molecular biology or genes, so that the growth rate, invasive ability, sensitivity to drugs, prognosis and other aspects have produced differences. Tumor heterogeneity includes between-tumor heterogeneity (genes and phenotypes differ between different tumor cells) and intratumor heterogeneity (genes and phenotypes also differ within the same tumor cell). Among them, intratumor heterogeneity can be divided into spatial heterogeneity (different regions of the same tumor) and temporal heterogeneity (primary tumor and secondary tumor are different). At present, scholars have begun to explore the diagnosis and treatment of tumors from the perspective of tumor heterogeneity, and have made continuous progress, striving to achieve precise diagnosis and precise treatment.
Most tumors are complex ecosystems that emerge and evolve under strong selective pressure from the microenvironment involving nutrition, metabolism, immunity, and therapeutic drugs. This pressure promotes the diversification of the tumor microenvironment (TME), which ultimately leads to a degree of tumor heterogeneity that enables rapid disease progression and drug resistance. In-depth study of tumor heterogeneity will help to understand the mechanism and evolution of tumors, and explain the reasons for drug resistance in the process of treatment. But so far, the biological relationship between different intratumoral clonal subpopulations and between clones and the microenvironment and other biological issues have been unclear. Alfa Oncology is developing various technologies to explore and solve the above problems, hoping to break through the problems and provide methods or drug guidance for clinical diagnosis, treatment and prevention of tumors.
Single-cell sequencing technology. Sequencing the entire tumor often masks the heterogeneity between cells. In order to explore the behavioral characteristics of individual tumor cells, tumor cell heterogeneity has become the focus of scientific and clinical experts engaged in tumor research. Emerging single-cell sequencing technologies analyze the genome, transcriptome or epigenetics at the single-cell level, revealing the degree of variation and interconnection between different cells within the same tumor, deepening the understanding of heterogeneity and promoting diagnosis and treatment development of technology.
Radiomics can provide tumor predictive signals, capture intratumor heterogeneity, and correlate with underlying gene expression patterns. This technology evaluates biological features such as tissue structure, blood flow, and metabolism through correlated image analysis. It can not only provide spatial information, but also repeat detection. Therefore, the use of imaging-related images to analyze specific parameters can quantify the degree of tumor heterogeneity and provide guidance for treatment planning and prognosis.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.